Damora Therapeutics, Inc. DMRA
Damora Therapeutics, Inc. (Nasdaq: DMRA) is a hematology drug developer. Its lead program, DMR-001, is in Phase 1 for Essential thrombocythemia (ET) and myelofibrosis (MF). Its next catalyst on record is DMR-002: First regulatory submission (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: DMR-002 — First regulatory submission (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| DMR-001 | Essential thrombocythemia (ET) and myelofibrosis (MF) with mutCALR mutations | antibody | Phase 1 |
| DMR-002 | mutCALR-driven myeloproliferative neoplasms | antibody | Pre-clinical |
| DMR-003 | mutCALR-driven myeloproliferative neoplasms | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.